Fenfluramine
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
Fenfluramine: From Epilepsy Syndromes to Proximal 16p11.2 Microdeletion Syndrome
One-Sentence Summary
Fenfluramine is a serotonin-releasing/5-HT2C agonist agent whose established use is in severe epilepsy syndromes (Dravet syndrome, Lennox-Gastaut syndrome); it is not marketed under the regulatory data in this evidence pack. The TxGNN model predicts a possible link to proximal 16p11.2 microdeletion syndrome, but this prediction is supported by zero clinical trials and zero publications — it is a model-score-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally recorded in this evidence pack (no license data); background text indicates use in Dravet syndrome and Lennox-Gastaut syndrome |
| Predicted New Indication | Proximal 16p11.2 microdeletion syndrome |
| TxGNN Prediction Score | 99.93% (rank 2543 among all candidates) |
| Evidence Level | L5 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data from DrugBank is flagged as a data gap in this evidence pack. Based on the available rationale text, fenfluramine is known as a serotonin-releasing agent / 5-HT2C receptor agonist, pharmacologically established for seizure control in Dravet syndrome and Lennox-Gastaut syndrome.
Proximal 16p11.2 microdeletion syndrome is a copy-number-variant genomic disorder whose clinical presentation can include obesity, autism-spectrum features, and (in some patients) seizures. The overlap with fenfluramine’s known pharmacology appears to be indirect — likely mediated through shared graph nodes such as “obesity” (fenfluramine’s historical appetite-suppressant use) or “seizure” — rather than a mechanism that addresses the syndrome’s underlying genetic cause.
Given this, the high TxGNN score most likely reflects graph-distance proximity through these intermediate nodes rather than a direct causal pathway. The mid-tier overall rank (2543) relative to the score’s near-ceiling value further suggests limited specificity for this particular disease-drug pair.
It is also worth noting that the other top-ranked predictions for this drug in the current evidence pack (hypervitaminosis, obsolete hypertelorism, frontorhiny) are explicitly flagged in their own rationale text as mechanistically implausible or likely graph noise — this pattern raises the bar for what independent evidence would be needed before treating the 16p11.2 prediction as more than a hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
Fenfluramine is not marketed under the regulatory data available (0 licenses on record); no authorization or product information is available to summarize.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests entirely on a TxGNN model score (L5) with no corroborating clinical trials or literature, and the proposed mechanistic link is indirect (via shared graph nodes rather than a disease-specific pathway). Combined with a Blocking data gap on TFDA safety labeling, this candidate does not meet the threshold to advance past S0.
To proceed, the following is needed:
- TFDA package insert warnings/contraindications (DG001, Blocking) — required before any S1 safety screening
- Confirmed mechanism-of-action data from DrugBank (DG002, High)
- Independent literature/mechanistic search specifically on serotonergic agents in 16p11.2 microdeletion syndrome (obesity or seizure sub-phenotypes)
- Formal confirmation of fenfluramine’s original approved indication(s) and licensing status, currently absent from this evidence pack
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.